TNF and heart failure: While blocking TNF-α in heart failure (HF) has been proven contraindicated in symptomatic (NYHA III and IV) patients (262, 263), anti-TNF-α may be a promising approach to prevent the early stages of cardiotoxicity from anti-PD-1 immunotherapy (200).